Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s stock price rose 28.2% during trading on Monday . The company traded as high as C$0.25 and last traded at C$0.25. Approximately 16,500 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 18,770 shares. The stock had previously closed at C$0.20.
Devonian Health Group Stock Performance
The company’s 50-day moving average price is C$0.18 and its two-hundred day moving average price is C$0.16. The company has a debt-to-equity ratio of 16.36, a quick ratio of 7.82 and a current ratio of 1.07. The stock has a market cap of C$37.06 million, a PE ratio of -8.93 and a beta of 0.86.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Read More
- Five stocks we like better than Devonian Health Group
- The Significance of Brokerage Rankings in Stock Selection
- Why Gold Loves Trump as Much as Trump Loves Gold
- Dividend Capture Strategy: What You Need to Know
- Google’s Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- Where Do I Find 52-Week Highs and Lows?
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
